MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$72,596K
Proceeds from issuance of
common stock from atm...
$15,408K
Proceeds from exercise of
warrants
$10,348K
Other financing
activities
$244K
Net cash provided by
financing activities
$36,184K
Canceled cashflow
$62,412K
Net increase
(decrease) in cash and cash...
$23,091K
Canceled cashflow
$13,093K
Repayment of convertible
notes
$54,912K
Payment of issuance
costs
$7,500K
Non-cash interest
expense related to the...
$57,211K
Other accrued
liabilities
$31,223K
Deferred revenue
$25,959K
Accounts payable
$20,918K
Stock-based compensation
expense
$9,870K
Paid-in-kind interest on
long-term debt
$9,093K
Other long-term
liabilities
$8,739K
Amortization of debt issuance
costs and discounts
$3,007K
Depreciation expense
$105K
Net cash used in
operating activities
-$13,093K
Canceled cashflow
$166,125K
Accounts receivable
$60,048K
Non-cash royalty revenue
$55,055K
Prepaids and other assets
$30,800K
Net loss
-$22,682K
Inventories
$10,633K
Back
Back
Cash Flow
source: myfinsight.com
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)